Avalo Therapeutics is a clinical stage biotechnology company based in Baltimore, MD, specializing in the development of therapies that target the LIGHT-signaling network to treat immune dysregulation. Their pipeline focuses on the creation of first-in-class biologics that aim to reduce LIGHT levels, thereby moderating immune dysregulation in various acute and chronic inflammatory disorders.
With a strong emphasis on dysregulated inflammation, Avalo Therapeutics aims to address autoimmune and inflammatory reactions in barrier organs by targeting the LIGHT-signaling network. Their innovative approach and commitment to developing high value potential therapies make them a key player in the field of immune dysregulation treatment.
Generated from the website